{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-142014","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.608762+00:00","generated_at":"2026-06-15T04:32:39.978472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change","bullets":["Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.","Cash, equivalents, investments $503.5M as of March 31, 2023; runway into 2026.","Zipalertinib pivotal study now enrolling at 100mg BID only; 150mg BID cohort discontinued per safety review.","First clinical data for CLN-049 (EHA) and CLN-619 (ASCO) to be presented mid-2023.","Licensed CLN-418 from Harbour Biomed for $25M upfront plus up to $563M in milestones and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-142014","json":"https://secwatch.observer/filing/0001193125-23-142014.json","markdown":"https://secwatch.observer/filing/0001193125-23-142014.md","text":"https://secwatch.observer/filing/0001193125-23-142014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/0001193125-23-142014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/d470233d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:32:39.978472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5d4ba787e8ac5da0a25fb2bcd076f0ef6b841fe","claim":"Cullinan Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Cullinan Oncology, Inc. announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/0001193125-23-142014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}